Physician profile
Patrick K Ellison
NPI 1184626244
$6,663.97
in general payments reported to CMS, 2019-2025
30 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $433 · 2021: $628 · 2022: $822 · 2023: $3,751 · 2024: $46.42 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,292 · Food and Beverage: $1,790 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,292.07 |
| Food and Beverage | $1,789.84 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $2,847.61 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $765.45 | 2019-2023 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $693.16 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $299.59 | 2023-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $284.15 | 2019-2025 | Lithovue, Ams 700 Cxr Rte Kit, Tria Firm |
| Abbvie INC. | $252.79 | 2019-2023 | |
| Pfizer INC. | $241.31 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $167.33 | 2019-2022 | |
| 180 Medical, INC. | $147.51 | 2021-2023 | |
| Coloplast Corp | $142.44 | 2019-2025 | Speedicath |
| Bayer Healthcare Pharmaceuticals INC. | $102.91 | 2019-2023 | |
| Urovant Sciences INC | $100.15 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $98.26 | 2025 | Bard Urinary Drainage Bag |
| Myovant Sciences INC. | $90.58 | 2022 | |
| Convatec INC. | $69.46 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $45.19 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $37.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.65 | 2019-2022 | |
| Urogen Pharma, INC. | $36.64 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $30.06 | 2022-2023 | Seglentis |
| Zyla Life Sciences, INC. | $26.98 | 2019 | |
| Sun Pharmaceutical Industries INC. | $23.60 | 2022 | |
| Tolmar, INC. | $22.52 | 2023 | |
| Ferring Pharmaceuticals INC. | $21.03 | 2019 | |
| Telix Pharmaceuticals | $17.87 | 2023 | Illuccix |
| Verity Pharmaceuticals INC. | $16.85 | 2023 | Trelstar |
| Neotract INC. | $13.22 | 2019 | |
| Halozyme INC | $13.07 | 2023 | |
| Richard Wolf Medical Instruments Corp. | $11.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.